Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults With Hereditary Angioedema (HAE)

Next Previous
Trial Profile

Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults With Hereditary Angioedema (HAE)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lonvoguran ziclumeran (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Intellia Therapeutics

Most Recent Events

  • 15 Jun 2025 According to an Intellia Therapeutics media release, results from the phase 1 portion of this study were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.
  • 15 Jun 2025 Results presented in the Intellia Therapeutics media release.
  • 08 May 2025 According to an Intellia Therapeutics media release, will present additional data from this study in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 on Sunday, June 15 in Glasgow, United Kingdom. And, expects to present new and longer-term data from the Phase 2 portion in the second half of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top